Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C16G2 Gel for Dental Caries
NCT02509845Phase 2Completed
- Sponsor
- Armata Pharmaceuticals
- Start
- Jul 2015
- Primary completion
- Feb 2016
- Modality
- Antimicrobial Peptides, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of C16G2 in dental caries (3 arms), sponsored by Armata Pharmaceuticals. Primary endpoint: Safety of multiple C16G2 Gel administrations as measured by adverse events. Started Jul 2015; status: completed.
02
Drugs
C16G2
03
Conditions
dental caries
Beyond the preview
Go deeper on NCT02509845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02509845.